Lisa McNeil, PhD, Vice President of Translational Medicine, leads the strategic planning, coordination, and execution of Elicio’s clinical immunogenicity program. She also supports pre-clinical assay development across areas of ongoing discovery in oncology and infectious disease. She brings over 15 years of translational immunology research and clinical development across immunotherapy, biologics and prophylactic, and therapeutic vaccines in big pharma and small biotech settings.
Before joining Elicio, Lisa worked at Genocea, where she and her team developed and validated immunogenicity assays for testing vaccine efficacy at all clinical stages. In addition, she led Genocea’s research efforts to develop a personalized adoptive T cell therapy against cancer. Lisa previously worked at Pfizer Vaccines, where she supported the development and discovery of infectious disease vaccines through flow cytometry and immune-based assays. While at Pfizer, she contributed to the licensure of Trumenba® for Neisseria meningitis Serogroup B.
Lisa received a Bachelor of Science degree in Biology from the University of Michigan and a PhD in Immunology and Molecular Pathogenesis from Emory University.
In her free time, Lisa enjoys hiking, traveling the world, and volunteering with children. If she were not a scientist, Lisa would be a food critic and is most happy while eating at restaurants in Boston and trying new cuisines with friends.